Search results
What You Need to Know About Humira's Low-Cost Competitors
Verywell Health via Yahoo News· 9 months agoAt least nine Humira biosimilars are coming to market, along with promises of lower costs for...
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance
AP Finance via Yahoo Finance· 11 months agoPatients who take the autoimmune disease treatment Humira may see some price relief when several...
Analysis-New Humira rivals likely to hit US market with small discounts in July
Reuters via Yahoo News· 11 months agoAt least four drugmakers are expected to launch new copycat versions of AbbVie's top-selling...
CVS will remove AbbVie's Humira from some drug reimbursement lists in April
Reuters via Yahoo News· 5 months agoCVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira...
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 4 weeks agoFears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as...
Could This Humira Biosimilar Be a Winner for Amgen?
Motley Fool· 1 year agoAt the end of January, Amgen (NASDAQ: AMGN) celebrated the U.S. launch of its biosimilar Amjevita to AbbVie's (NYSE: ABBV) star immunology drug called...
Do Humira Biosimilars Threaten AbbVie's Dividend?
Motley Fool· 1 year agoPharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current...
Boehringer launches 81% discounted biosimilar of AbbVie's Humira
Reuters via Yahoo News· 8 months ago(Reuters) -Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar...
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Reuters via Yahoo Finance· 1 month agoCigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no...
FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high
Reuters via Yahoo Finance· 1 year agoU.S. patients will finally get access to cheaper versions of AbbVie Inc’s blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen ...